INTRODUCTION
Breast cancer is the leading type of cancer diagnosis of females in North America and second to lung cancer as a leading cause of cancer related death [1] . In both clinical practice and research, breast cancer is categorized into subtypes on the bases of receptor status as these determine the course of treatment. Estrogen-receptor (ER), progesterone-receptor (PR), and human epidermal growth factor receptor 2 (HER2), are the three receptors whose combinatorial presence or absence (positivity or negativity status) determine treatment options and breast cancer subtype. Through gene expression data, breast cancer can be categorized into several molecular subtypes, including normal-like, luminal A, luminal B, HER2-enriched, and basal-like.
Magnetic resonance imaging (MRI) uses a powerful magnetic field, radio waves and a computer to produce detailed pictures of the structures within the breast. Breast MRI is the most precise method for detecting breast cancer. It is utilized for breast cancer screening, as an additional diagnostic test in pretherapeutic breast cancer staging, monitoring of primary systemic therapies, or for resolving ambiguous diagnostic situations where direct biopsy is impermissible. With breast MRI data, breast cancer can be categorized into one of four pathological stages based on the TNM (tumor, nodes, metastasis) staging system. Through radiogenomics, a fast-growing field of research, scientists aim to discover clinically actionable associations between high throughput features extracted from medical images (radiomics) and high throughput genomic data [2] . Focused primarily on cancer, the overarching goal of radiogenomics is to advance precision oncology by enabling deeper understanding of cancer biology, discovery of cancer phenotypes, and development of more accurate predictive models for diagnosis, prognosis, and clinical response to treatment. A limited but rapidly increasing body of literature suggests that radiogenomics hold much promise [3] , however small sample sizes and technical issues with respect to data acquisition have led to continuing debate regarding the reproducibility and robustness of study findings [4] .
In this study, we investigated the feasibility of integrating two data sources: radiomic and genomic data, to identify clinical phenotypes of invasive breast cancer. First, we leveraged imaging data from The Cancer Imaging Archive (TCIA) and genomic data from The Cancer Genome Atlas (TCGA) to perform the study. Briefly, we focused on predicting pathological stage and molecular receptor status, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2); two very important factors of cancer prognosis and treatment response. Second, we investigated the potential of deep learning (DL) for the above predictive tasks. DL algorithms are well established as powerful feature learners with comparative and often superior performance compared to conventional machine learning algorithms, while requiring little or no feature engineering overhead . However, there are only a handful of radiogenomic studies that leverage DL, primarily due to unavailability or inaccessibility of sufficiently large datasets. In addition, most radiomics studies rely on manual curation by an expert clinician to indicate tumor location within the medical image. In contrast, our study attempts to alleviate the human-in-the-loop requirement by analyzing full images absent of manual curation, and not a region of interest extracted around the indicated location.
METHODS

Dataset
We performed experimental analysis on breast magnetic resonance imaging (MRI) data from 118 breast cancer patients provided by The Cancer Imaging Archive (TCIA) [5] . We utilized sagittal axis, T1-weighted images of both pre-contrast and post-contrast enhanced images, depending on availability. An example of MRI slice is shown in Figure 1 . In total, our imaging dataset consisted of 213 MRI sets; 41, 130, and 42 breast cancer cases of pathological stage I, II, and III respectively. The corresponding gene expression data for each case was obtained from The Cancer Genomic Atlas-Breast Invasive Carcinoma (TCGA-BRCA) [6] .
The genomic data utilized in this study consists of gene expressions of 70 genes, which is based on the list provided in [4] .The molecular receptor status is a binary, positive ("+") or negative ("-"), indicating the presence of a protein (HER2), or whether or not a breast cancer needs hormones to grow (ER/PR). Information about the patients' molecular receptor status was extracted from TCIA. Estrogen-receptor (ER) receptor status, ER+ and ER-, indicate whether or not a breast cancer needs estrogen hormones to grow. The dataset included 170 cases of type ER+, and 43 cases of type ER-. The progesterone-receptor (PR) status, PR+ and PR-, indicates whether or not a breast cancer needs progesterone hormones to grow. The dataset included 155 cases of type PR+ and 58 cases of type PR-. The human epidermal growth factor receptor 2 (HER2) status, HER2+ and HER2-, indicates the prevalence of the HER2 protein on the surface of some breast cancer cells, which is involved in cell growth and survival. The dataset included 37 cases of type HER2+ and 122 cases of type HER2-. 
2.2� Deep Neural Networks for Radiogenomic Analysis
Our approach is based on the Convolutional Neural Network (CNN), a widely popular DL model for medical image analysis and classification [7] . To alleviate the need of manual annotation of the tumor in the MRI, we applied 3-D convolutional filters. The feed-forwarded outputs of the convolution layers were combined with the 70 gene expressions, names listed in Table 1 , then fed to the fully-connected layers. Figure 2 illustrates the architecture of the proposed method.
Figure 2. A hybrid Convolutional Neural Network model for inputs of radiogenomics data.
We implemented the proposed DL networks using the Keras[8] and TensorFlow [9] backend on Python environment, and ran the experiments on the Summitdev computers in Oak Ridge Leadership Computing Facility (OLCF), which equips NVIDIA P100 GPU with 16GB of memory. A hyper-parameter optimization technique based on random search strategy was utilized to determine the optimal number of convolution filters, number of fully-connected nodes, and number of nodes for each one of the predictive tasks. AFF2  AKT1  ATM  AURKB  BCL2  BRCA1  BRCA2   BRIP1  BUB1  CAMK1D  CBFB  CCND1  CCND3  CCNE1   CDC20  CDC45  CDCA3  CDCA4  CDH1  CDK3  CDK4   CDKN1B  CDKN2A  CDKN2B  CHEK1  CHEK2  CTCF  EGFR   ERBB2  FOXA1  FOXM1  GATA3  HDAC2  IGF1R  KIF2C   KIFC1  MAP2K4  MAP3K1  MDM1  MDM2  MDM4  MTAP   MTHFD1L  MYC  NBN  NCOR1  NF1  PAK1  PI4KB   PIK3CA  PIK3R1  PPP2R1A  PPP2R2A  PPP2R2B  PTEN  PTPN22   PTPRD  RAD51AP1  RAD51C  RB1  RSF1  RUNX1  SF3B1   TBX3  TBX4  TBX5  TP53  TTK  UBE2C  ZNF703 
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RESULTS
We performed patient-level 10-fold cross validation tests to avoid intra-patient bias. Due to the limited number of training samples, especially for the radiomics data, we augmented the training data by flipping images horizontally and/or vertically, and/or reversing the order of slides, resulting in 1,400~1,500 training samples for the 3-D CNN. Results of the classification tasks were listed in Table 2 in the form of Area Under Receiver Operating Characteristics (AUC) curves. The micro-averaged AUC scores and their standard deviations were calculated by the scikit-learn package [10] available on Python 3 programming environments. For the reference purpose, we
Genomic features performed better than radiomic features in predicting ER, PR and HER2. Such results are expected as the biomarkers are closely related to the genomic profiles of tumors, and is in accordance to previous study [4] . Radiomicbased CNNs produced substantially higher AUC score than genomic features. Overall, integrating both radiomic and genomic information boosted performance even further, achieving the highest AUC scores for predicting pathological stage, ER, PR, and HER2 status. Receiver Operating Characteristic (ROC) curves of the classification tasks are illustrated in Figure 3 . Table 2 . Classification results of the deep neural networks for genomics, radiomics, and radiogenomics data. Performance measurement is the Area Under Receiver Operating Characteristics (AUC) curves. 
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4.� DISCUSSION
In this study, we studied the feasibility of deep learning in radiogenomics for identifying clinical phenotypes of invasive breast cancer. Compared to the handful of studies published on the topic, the main advantage of our study is the deployment of 3D deep learning for analyzing full MRI volumes without the need to indicate the tumor location. Our results suggest that the genomic data have high predictive power for predicting molecular receptor status but radiomic data are more predictive of pathological stage. Combining both radiomic and genomic information using deep learning produced higher classification performance for pathological stage, ER, PR, and HER2 status.
A main limitation of our study was the limited number of cases available for training the proposed 3D CNN. In the future, we plan to extend the study and leverage not only the sagittal T1 sequences but also other MRI sequences available in TCIA. In addition, we composed gene expression features based on the choice of 70 genes suggested by other study. Future studies will include feature selection from the TCGA-BRCA archive. Lastly, to mitigate the challenge of patient data availability with known ground truth, we may leverage openly available breast MRI datasets to train the convolution filters based on semi-supervised learning mechanism.
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